Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The aim of the present study was to explore whether endogenous activation of different purine receptors by ATP and adenosine contributes to or inhibits excess glutamate release evoked by ischemic-like conditions in rat hippocampal slices. Combined oxygen-glucose deprivation (OGD) elicited a substantial, [Ca2+]o-independent release of [3H]glutamate, which was tetrodotoxin (1 μM)-sensitive and temperature-dependent. The P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS, 0.1-10 μM), and the selective P2X7 receptor antagonist Brilliant Blue G (1-100 nM), decreased OGD-evoked [3H]glutamate efflux indicating that endogenous ATP facilitates ischemia-evoked glutamate release. The selective A1-receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 0.1-250 nM) and the selective A2A receptor antagonists 4-(2-[7-amino-2-)2-furyl(triazolo-[1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385, 0.1-20 nM) and 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1, 5-c]pyrimidine (SCH58261, 2-100 nM) decreased OGD-evoked [3H]glutamate efflux, indicating that endogenous adenosine also facilitates glutamate release under these conditions. The effect of DPCPX and ZM241385 was reversed, whereas the action of P2 receptor antagonists was potentiated by the selective ecto-ATPase inhibitor 6-N,N-diethyl-D-β,γ-dibromomethyleneATP (ARL67156, 50 μM). The binding characteristic of the A2A ligand [3H]CGS21680 to hippocampal membranes did not change significantly in response to OGD. Taken together these data suggest that while A1 receptors might became desensitized, A2A and P2X receptor-mediated facilitation of glutamate release by endogenous ATP and its breakdown product adenosine remains operational under long-term OGD. Therefore the inhibition of P2X/A2A receptors rather than the stimulation of A1 adenosine receptors could be an effective approach to attenuate glutamatergic excitotoxicity and thereby counteract ischemia-induced neurodegeneration.

Original languageEnglish
Pages (from-to)99-111
Number of pages13
JournalNeuroscience
Volume149
Issue number1
DOIs
Publication statusPublished - Oct 12 2007

Fingerprint

Glutamic Acid
Hippocampus
Oxygen
Glucose
Adenosine
Adenosine Triphosphate
Ischemia
Purinergic P2X7 Receptors
Adenosine A1 Receptors
Purinergic Receptors
Tetrodotoxin
Phenol
Ligands
Temperature
Acids
Membranes
1,3-dipropyl-8-cyclopentylxanthine

Keywords

  • A receptor
  • hippocampus
  • ischemia
  • P2 receptor
  • receptor binding
  • release

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus. / Sperlágh, B.; Zsilla, G.; Baranyi, M.; Illes, P.; Vízi, E.

In: Neuroscience, Vol. 149, No. 1, 12.10.2007, p. 99-111.

Research output: Contribution to journalArticle

@article{803f4d400e334d8a8b634567a262bfe6,
title = "Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus",
abstract = "The aim of the present study was to explore whether endogenous activation of different purine receptors by ATP and adenosine contributes to or inhibits excess glutamate release evoked by ischemic-like conditions in rat hippocampal slices. Combined oxygen-glucose deprivation (OGD) elicited a substantial, [Ca2+]o-independent release of [3H]glutamate, which was tetrodotoxin (1 μM)-sensitive and temperature-dependent. The P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS, 0.1-10 μM), and the selective P2X7 receptor antagonist Brilliant Blue G (1-100 nM), decreased OGD-evoked [3H]glutamate efflux indicating that endogenous ATP facilitates ischemia-evoked glutamate release. The selective A1-receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 0.1-250 nM) and the selective A2A receptor antagonists 4-(2-[7-amino-2-)2-furyl(triazolo-[1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385, 0.1-20 nM) and 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1, 5-c]pyrimidine (SCH58261, 2-100 nM) decreased OGD-evoked [3H]glutamate efflux, indicating that endogenous adenosine also facilitates glutamate release under these conditions. The effect of DPCPX and ZM241385 was reversed, whereas the action of P2 receptor antagonists was potentiated by the selective ecto-ATPase inhibitor 6-N,N-diethyl-D-β,γ-dibromomethyleneATP (ARL67156, 50 μM). The binding characteristic of the A2A ligand [3H]CGS21680 to hippocampal membranes did not change significantly in response to OGD. Taken together these data suggest that while A1 receptors might became desensitized, A2A and P2X receptor-mediated facilitation of glutamate release by endogenous ATP and its breakdown product adenosine remains operational under long-term OGD. Therefore the inhibition of P2X/A2A receptors rather than the stimulation of A1 adenosine receptors could be an effective approach to attenuate glutamatergic excitotoxicity and thereby counteract ischemia-induced neurodegeneration.",
keywords = "A receptor, hippocampus, ischemia, P2 receptor, receptor binding, release",
author = "B. Sperl{\'a}gh and G. Zsilla and M. Baranyi and P. Illes and E. V{\'i}zi",
year = "2007",
month = "10",
day = "12",
doi = "10.1016/j.neuroscience.2007.07.035",
language = "English",
volume = "149",
pages = "99--111",
journal = "Neuroscience",
issn = "0306-4522",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Purinergic modulation of glutamate release under ischemic-like conditions in the hippocampus

AU - Sperlágh, B.

AU - Zsilla, G.

AU - Baranyi, M.

AU - Illes, P.

AU - Vízi, E.

PY - 2007/10/12

Y1 - 2007/10/12

N2 - The aim of the present study was to explore whether endogenous activation of different purine receptors by ATP and adenosine contributes to or inhibits excess glutamate release evoked by ischemic-like conditions in rat hippocampal slices. Combined oxygen-glucose deprivation (OGD) elicited a substantial, [Ca2+]o-independent release of [3H]glutamate, which was tetrodotoxin (1 μM)-sensitive and temperature-dependent. The P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS, 0.1-10 μM), and the selective P2X7 receptor antagonist Brilliant Blue G (1-100 nM), decreased OGD-evoked [3H]glutamate efflux indicating that endogenous ATP facilitates ischemia-evoked glutamate release. The selective A1-receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 0.1-250 nM) and the selective A2A receptor antagonists 4-(2-[7-amino-2-)2-furyl(triazolo-[1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385, 0.1-20 nM) and 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1, 5-c]pyrimidine (SCH58261, 2-100 nM) decreased OGD-evoked [3H]glutamate efflux, indicating that endogenous adenosine also facilitates glutamate release under these conditions. The effect of DPCPX and ZM241385 was reversed, whereas the action of P2 receptor antagonists was potentiated by the selective ecto-ATPase inhibitor 6-N,N-diethyl-D-β,γ-dibromomethyleneATP (ARL67156, 50 μM). The binding characteristic of the A2A ligand [3H]CGS21680 to hippocampal membranes did not change significantly in response to OGD. Taken together these data suggest that while A1 receptors might became desensitized, A2A and P2X receptor-mediated facilitation of glutamate release by endogenous ATP and its breakdown product adenosine remains operational under long-term OGD. Therefore the inhibition of P2X/A2A receptors rather than the stimulation of A1 adenosine receptors could be an effective approach to attenuate glutamatergic excitotoxicity and thereby counteract ischemia-induced neurodegeneration.

AB - The aim of the present study was to explore whether endogenous activation of different purine receptors by ATP and adenosine contributes to or inhibits excess glutamate release evoked by ischemic-like conditions in rat hippocampal slices. Combined oxygen-glucose deprivation (OGD) elicited a substantial, [Ca2+]o-independent release of [3H]glutamate, which was tetrodotoxin (1 μM)-sensitive and temperature-dependent. The P2 receptor antagonist pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid (PPADS, 0.1-10 μM), and the selective P2X7 receptor antagonist Brilliant Blue G (1-100 nM), decreased OGD-evoked [3H]glutamate efflux indicating that endogenous ATP facilitates ischemia-evoked glutamate release. The selective A1-receptor antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX, 0.1-250 nM) and the selective A2A receptor antagonists 4-(2-[7-amino-2-)2-furyl(triazolo-[1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385, 0.1-20 nM) and 7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1, 5-c]pyrimidine (SCH58261, 2-100 nM) decreased OGD-evoked [3H]glutamate efflux, indicating that endogenous adenosine also facilitates glutamate release under these conditions. The effect of DPCPX and ZM241385 was reversed, whereas the action of P2 receptor antagonists was potentiated by the selective ecto-ATPase inhibitor 6-N,N-diethyl-D-β,γ-dibromomethyleneATP (ARL67156, 50 μM). The binding characteristic of the A2A ligand [3H]CGS21680 to hippocampal membranes did not change significantly in response to OGD. Taken together these data suggest that while A1 receptors might became desensitized, A2A and P2X receptor-mediated facilitation of glutamate release by endogenous ATP and its breakdown product adenosine remains operational under long-term OGD. Therefore the inhibition of P2X/A2A receptors rather than the stimulation of A1 adenosine receptors could be an effective approach to attenuate glutamatergic excitotoxicity and thereby counteract ischemia-induced neurodegeneration.

KW - A receptor

KW - hippocampus

KW - ischemia

KW - P2 receptor

KW - receptor binding

KW - release

UR - http://www.scopus.com/inward/record.url?scp=34848843452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848843452&partnerID=8YFLogxK

U2 - 10.1016/j.neuroscience.2007.07.035

DO - 10.1016/j.neuroscience.2007.07.035

M3 - Article

C2 - 17850981

AN - SCOPUS:34848843452

VL - 149

SP - 99

EP - 111

JO - Neuroscience

JF - Neuroscience

SN - 0306-4522

IS - 1

ER -